Effect of ATG-F on B-cell reconstitution after hematopoietic stem cell transplantation
| Autor: | Ulrich Grigoleit, Hermann Einsele, Hans-Peter Tony, Khalid Muhammad, Gernot Stuhler, Petra Roll |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Graft Rejection Male Time Factors Transplantation Conditioning Globulin medicine.medical_treatment B-Lymphocyte Subsets Hematopoietic stem cell transplantation Normal values CD19 Immunophenotyping Young Adult Immune system medicine Humans Transplantation Homologous In patient B cell Aged Antilymphocyte Serum B-Lymphocytes biology business.industry Graft Survival Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged Immunoglobulin Class Switching Tissue Donors Transplantation Phenotype Treatment Outcome medicine.anatomical_structure Antigens Surface Immunology biology.protein Female Somatic Hypermutation Immunoglobulin business Immunologic Memory Immunosuppressive Agents |
| Zdroj: | European Journal of Haematology. 95:514-523 |
| ISSN: | 0902-4441 |
| DOI: | 10.1111/ejh.12524 |
| Popis: | Antithymocyte globulin Fresenius (ATG-F) is used before hematopoietic stem cell transplantation to prevent graft rejection and graft-versus-host disease in patients with HLA-matched unrelated donors or mismatched volunteers. However, little is known about the effect of ATG-F on the reconstitution of B-cell subsets. Sixty-seven patients were longitudinally studied at day 15, day 30, and then monthly after hematopoietic stem cell transplantation. Conditioning regimes included ATG-F, which was infused at days 3, 2 and 1 at a dosage of 10 mg/kg/d. Twenty-seven patients received conditioning regimes without ATG. ATG-treated patients showed a significant delay of CD19+ B cells in the early recovery period. The absolute numbers of circulating CD19+ B cells were significantly lower (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |